NICE recommends new triple therapy option for type 2 diabetesBMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i5472 (Published 10 October 2016) Cite this as: BMJ 2016;355:i5472
- Jacqui Wise
Dapagliflozin (marketed as Forxiga) has been recommended as part of triple therapy for patients with type 2 diabetes, giving doctors another prescribing option for patients with uncontrolled blood sugar.
Draft guidance from the National Institute for Health and Care Excellence (NICE) has recommended dapagliflozin in combination with metformin and a sulfonylurea as an option for treating type 2 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial